XENE fundamentals
Key facts
Market capitalization2.64 BUSD
Basic EPS (TTM)−3.01USD
Founded1996
CEOIan C. Mortimer
Websitexenon-pharma.com
About
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−68.00 M
−51.00 M
−34.00 M
−17.00 M
0.00
Revenue
Net income
Net margin %
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
XENE does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company